

Title

Migraine & drug treatment

Reference Number: RDF2045-23

Date of Response: 14/12//23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

- 1. Does the trust commission/fund Botox treatment for migraine (Y/N)?*
- 2. Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?*
- 3. Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?*
- 4. In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.*

The Trust can confirm that it holds information that you have requested in the above questions. This information is exempt under Section 21 of the Freedom of Information Act because it is reasonably accessible to you. The information you requested can be accessed via the following link:

<https://www.royaldevon.nhs.uk/media/x53lzqwi/foi-rdf1334-23-migraine-care-planning.pdf>

All Trust responses to Freedom of Information requests can be found at the following link:

<https://royaldevon.nhs.uk/about-us/information-governance/freedom-of-information-foi-and-environmental-information-regulations-eir/foi-disclosure-log/>

Section 21 of the Freedom of Information Act exempts disclosure of information that is reasonably accessible by other means. The terms of

this exemption mean that the Trust does not have to consider whether or not it would be in the public interest for you to have the information.

5. *How many patients have been treated with the following drugs in the past 4 months:*

<i>Drug</i>	<i>Total Trust patients.</i>
<i>Atogepant (Aquipta) – any disease</i>	<i>0</i>
<i>Erenumab (Aimovig) - any disease</i>	<i>112</i>
<i>Eptinezumab (Vyepsti) – any disease</i>	<i>0</i>
<i>Fremanezumab (Ajovy) - any disease</i>	<i>130</i>
<i>Galcanezumab (Emgality) - any disease</i>	<i>18</i>
<i>Rimegepant (Vydura) – any disease</i>	<i>0</i>
<i>Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY</i>	<i>40</i>